Acupoint Injection of Autologous Stromal Vascular Fraction and Allogeneic Adipose-Derived Stem Cells to Treat Hip Dysplasia in Dogs

• Published in: Stem Cells International Vol. 2014; no. 2014; pp. 191 - 196
• Main Authors: Nardi, Nance Beyer, Braga, Luisa Maria Gomes de Macedo, da Silva, Ariel Silveira, Selbach, Isabel, Silveira, Maiele Dornelles, Marx, Camila, Camassola, Melissa
• Format: Journal Article
• Language: English
• Published: Cairo, Egypt Hindawi Limiteds 01-01-2014; Hindawi Publishing Corporation; John Wiley & Sons, Inc; Hindawi Limited
• Subjects: Acupuncture; Adipose tissue; Animals; Bone marrow; Care and treatment; Drug therapy; Dysplasia; Fractions; Growth factors; Health aspects; Injection; Pain; Stem cells; Studies; Transplantation; Transplants & implants; Veterinary medicine; Brazil; Rio Grande
• ISSN: 1687-966X; 1687-9678; 1687-9678
• DOI: 10.1155/2014/391274

Stem cells isolated from adipose tissue show great therapeutic potential in veterinary medicine, but some points such as the use of fresh or cultured cells and route of administration need better knowledge. This study aimed to evaluate the effect of autologous stromal vascular fraction (SVF, n = 4 ) or allogeneic cultured adipose-derived stem cells (ASCs, n = 5 ) injected into acupuncture points in dogs with hip dysplasia and weak response to drug therapy. Canine ASCs have proliferation and differentiation potential similar to ASCs from other species. After the first week of treatment, clinical evaluation showed marked improvement compared with baseline results in all patients treated with autologous SVF and three of the dogs treated with allogeneic ASCs. On days 15 and 30, all dogs showed improvement in range of motion, lameness at trot, and pain on manipulation of the joints, except for one ASC-treated patient. Positive results were more clearly seen in the SVF-treated group. These results show that autologous SVF or allogeneic ASCs can be safely used in acupoint injection for treating hip dysplasia in dogs and represent an important therapeutic alternative for this type of pathology. Further studies are necessary to assess a possible advantage of SVF cells in treating joint diseases.